Genprex Launch IPO For Trials Of New Gene Therapy Lung Cancer Treatment – Forbes
Forbes |
Genprex Launch IPO For Trials Of New Gene Therapy Lung Cancer Treatment
Forbes Genprex is raising capital through their S-1 IPO offering with the intent to complete their IPO and list on the Nasdaq Exchange under the ticker NASDAQ: GNPX. The offering is for $6.5 million at $5/share with a valuation of $58.5 mill before the … |
